Treatment outcome of patients with anaplastic thyroid cancer: A single center experience

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 352-357

  Lim, Sun Min ^a   Shin, Sang Joon ^a,b   Chung, Woong Youn ^a   Park, Cheong Soo ^a   Nam, Kee Hyun ^a   Kang, Sang Wook ^a   Keum, Ki Chang ^a   Kim, Joo Hang ^a,b   Cho, Jae Yong ^a   Hong, Yun Kyoung ^c   Cho, Byoung Chul ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c JE UK Institute for Cancer Research   (South Korea)

Author keywords

Anaplastic thyroid cancer; Chemoradiotherapy; Prognosis; Survival; Treatment outcome

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ANAPLASTIC THYROID CANCER; ASPIRATION PNEUMONIA; BLOOD TOXICITY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERPIGMENTATION; MALE; MEDICAL RECORD; MUCOSA INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; REVIEW; THYROID CANCER; THYROID SURGERY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84863171879     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.352     Document Type: Review

References (22)

1. Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:1330-5.
2. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 1997;79:564-73.
3. McIver B, Hay ID, Giuffrida DF, Dvorak CE, Grant CS, Thompson GB, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-34.
4. Pierie J P, Muzikansky A, Gaz RD, Faquin WC, Ott MJ. The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma. Ann Surg Oncol 2002;9:57-64.
5. Kim JH, Leeper RD. Treatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination Adriamycin and radiation therapy. A new approach. Cancer 1983;52:954-7.
6. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-5.
7. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991;14:475-80.
8. Ain KB. Management of undifferentiated thyroid cancer. Bail-lieres Best Pract Res Clin Endocrinol Metab 2000;14:615-29.
9. Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008;31:460-4.
10. Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006;107:1786-92.
11. Union Internationale Contre le Cancer. TNM classifcation of malignant tumors. 6th ed. New York: Wiley-Liss; 2002.
12. Chang HS, Nam KH, Chung WY, Park CS. Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005;46:759-64.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45: 228-47.
14. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Lev-endag PC. Multimodality treatment for anaplastic thyroid carcino-ma--treatment outcome in 75 patients. Radiother Oncol 2009;92: 100-4.
15. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-53.
16. De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:1137-43.
17. Troch M, Koperek O, Scheuba C, Dieckmann K, Hoffmann M, Niederle B, et al. High effcacy of concomitant treatment of undif-ferentiated (anaplastic) thyroid cancer with radiation and docetax-el. J Clin Endocrinol Metab 2010;95:E54-7.
18. Wiseman SM, Masoudi H, Niblock P, Turbin D, Rajput A, Hay J, et al. Anaplastic thyroid carcinoma: expression profle of targets for therapy offers new insights for disease treatment. Ann Surg Oncol 2007;14:719-29.
19. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59.
20. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xeno-grafts in nude mice. Clin Cancer Res 2006;12:600-7.
21. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother 2008;62:559-63.
22. Antonelli A, Ferrari SM, Fallahi P, Berti P, Materazzi G, Barani L, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fne-needle aspiration used for chemosensitivity tests. Clin En-docrinol (Oxf) 2008;69:148-52.